Breast milk
grows babies' bodies, fuels neurodevelopment, provides essential immunofactors
and safeguards against famine and disease — why, then, does science know more
about tomatoes than mother's milk? Katie Hinde shares insights into this
complex, life-giving substance and discusses the major gaps scientific research
still needs to fill so we can better understand it.
Your Web destination for the latest in Evidence based Obstetrics, Gynecology and Women’s health.
Sunday, April 30, 2017
In case you missed it: Here are the top 5 posts this month.
Ethicon
STRATAFIX™ Spiral Plus Devices transforms wound closure experience for
surgeons.
Ethicon has
launched Stratafix Spiral PDS Plus and Stratafix Spiral Monocryl Plus Knotless
Tissue Control Devices that provides a unique edge over traditional suturing.
Stratafix
sutures enables more strength, consistency, security and efficiency over its
predecessors because the surgeon can manage tension and control tissue
approximation with each pass. It also eliminates the need to tie knots.
Mayo Clinic
Tampon Test for detecting Endometrial Cancer at early stage.
There is no
standard screening test to identify endometrial cancer, hence it is often
detected late when the disease has already advanced.
Mayo clinic
expert Jamie N. Bakkum-Gamez, M.D. and her team are in the process of
developing a simple screening test that can be done at home using a tampon. It
is based on the concept of detecting tumor DNA hypermethylation in vaginal pool
DNA picked up by ordinary tampon.
At last, a
no surgery, no knife, noninvasive treatment for uterine fibroid receives
European approval.
Mirabilis
Medical, a Seattle based company received CE Mark authorization for marketing of
the Mirabilis System for treatment of uterine fibroids throughout the European
Union. It also announced that it had
received a green signal from US-FDA to begin its clinical studies in US.
The
Mirabilis system is a High-Intensity Focused Ultrasound (HIFU) system consists
of an ultrasound system that has two parts: the imaging part and the therapy
part.
Synthetic
progestogens, but not natural progesterone, lowers miscarriage risk among women
with unexplained RPL: Systematic review and meta-analysis.
Women taking
progestogens have a 28% lower risk of miscarriage (RR 0.72; 95% CI
0.53-0.97). and 7% higher chances of
live births as compared to women who did not receive any supplementation. (RR
1.07, 95% CI 1.02–1.15).
The
Meta-analysis included 10 trials comprising a total of 1,586 women with history
of recurrent miscarriage.
Sperms used
as vehicle for targeted drug delivery in gynecological cancers.
Sperms are
not just for baby-making anymore, but can be used as cargo agents for
delivering drugs inside the body.
Getting the
chemotherapeutic agent to only kill the tumor cells without affecting the
normal cells is a dream come true in area of cancer therapeutics because of
Targeted drug delivery systems(TDDS).
Targeted
drug delivery systems using polymeric nanoparticles have opened up new avenues
in cancer chemotherapy. Liposomes have
shown to be effective among an array of nano- and microcarriers but have the
drawback of dilution by body fluids, decreased penetration and uptake by
non-target tissues.
Friday, April 28, 2017
Video of the day: DNA-Past to Present 2017
National DNA
Day is a unique day when students, teachers and the public can learn more about
genetics and genomics! The day commemorates the completion of the Human Genome
Project in April 2003, and the discovery of DNA's double helix in 1953.
Virtual reality adds a new dimension to pain management in labor.
appliedVR |
Virtual
Reality is no longer just a part of Sci-Fi movies but it has moved from realm of
fiction to world of reality. Besides being used in virtual reality gaming, the
technology holds endless potential for application in healthcare industry.
It finds its
application in numerous areas of medicine like medical education, training
young surgeons for reality of OR, treating patients with mental health problems
and relieving acute and chronic pain, including the pain during labor.
Virtual
Reality ability to distract mother from pain during labor could redefine the
need of epidural in childbirth.
Dr. Ralph
Anderson, an obstetrician-gynecologist at Orange Regional Medical Center in
Middletown, New York found that by giving expectant mothers VR headsets that
immerse them in specially designed 3D environments, anxiety and pain were often
reduced.
“I wanted to
make their experience better,” Anderson said of his patients. “I started using
this device mainly around the office with my staff, but my idea all along was
to find a way to use it in the hospital.”
He got the
first opportunity to use VR during labor when one of his patient Erin Martucci
refused to have an epidural shot and asked for an alternative.
She was
given a pre-programmed Samsung Gear VR headset, with instructions like “focus
on the birds” and “remember to breathe” delivered by a pre-recorded narrator.
The VR
headset took her out of hospital room and deposited her on a scenic overlook of
California’s Big Sur. The crashing waves, soothing sounds and helpful
instructions were able to help this mother manage her pain.
Minutes
after taking off the device she gave birth to a beautiful baby girl.
Martucci is
believed to be the first woman to use virtual reality (VR) for pain management
during labor.
Besides its application
in labor pain management Dr.Anderson has used this technology for managing antenatal patients who are confined to bed for
long to help them get over the boredom, cervical biopsies or in difficult pelvic exams and placement of balloons
for induction of labor.
The company
that created the virtual environment for Dr Anderson is AppliedVR, it has
partnered with Cedars-Sinai Medical Center in Los Angeles for clinical studies.
Childbirth is
just one example of VR based pain management, it can be very useful in managing
pain due to burns also.
VR has the
potential to suppress pain in other medical procedures, too. “Because of its
immersive and distractive nature, researchers believe that VR may be safer and
more effective than traditional analgesic methods,” researchers from Shanghai’s
Tongji University wrote in a June 2016 evaluation of the use of VR for pain
management.
Researchers
at Los Angeles-based Cedars-Sinai Medical Center are also further exploring the
possibility of the use of VR for chronic pain management.
Patients
having chronic pain are using Samsung Gear VR technology once during their inpatient
stay and later completing a survey about the experience.
Dr. Brennan
Spiegel, director of Cedars-Sinai Health Services Research, envisions the
eventual need for VR pharmacies — libraries of different types of VR content
that specialists can match to the needs of specific patients.
The basics
of VR kit is the headset that looks like a thick pair of goggles which goes
over your eyes, and a smartphone that is clipped in front of the handset.
More
expensive high end headsets are connected to a computer to run the apps and
games. There are other number of accessories to simulate the experience of
being in another world.
VR devices have
own app store where you can view the apps and download it.
Virtual
Reality | Cedars-Sinai
USPSTF final recommendation statement favor screening for preeclampsia throughout pregnancy.
The US
Preventive Services Task Force (USPSTF) today issued its final recommendations
for preeclampsia screening by monitoring the blood pressure throughout pregnancy
with grade B, meaning there exists substantial net benefit for the mother and
infant because of screening.
The
recommendations, accompanying editorial and systematic review evidence was
published online 25 April 2017 in JAMA.
USPSTF has
earlier released a draft recommendation on September 27, 2016 which was open to
public comments till October 2017.
The task
force last full review of this topic was in 1996. The topic was again reviewed recently in light of new evidence and change in definition of preeclampsia.
The current
recommendation states that Blood Pressure measurement should be done at each
antenatal visit. No timing interval is mentioned.
The
screening applies to all pregnant women without a known diagnosis of preeclampsia
or being at high risk for the disease.
Conditions
associated with increased risks are previous history of eclampsia or
preeclampsia (particularly early-onset preeclampsia), medical morbidities
associated includes DM 1 or 2, GDM, chronic hypertension, renal disease, and
autoimmune diseases), previous history of adverse pregnancy outcome and
multifetal gestation.
Other risk
factors include nulliparity, obesity, African American race, low socioeconomic
status, and advanced maternal age.
Evidence did
not suggest point of care urine testing when screening for preeclampsia because
it alone could not predict the health outcome.
Recently
revised criteria for the diagnosis of preeclampsia include:
- elevated blood pressure (≥140/90 mm Hg on 2 occasions 4 hours apart, after 20 weeks of gestation)
- and either proteinuria (≥300 mg/dL on a 24-hour urine protein test, protein to creatinine ratio of ≥0.3 mg/mmol, or urine protein dipstick reading >1 if quantitative analysis is not available)
- or, in the absence of proteinuria, thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or cerebral or visual symptoms.
The USPSTF
further recommends low dose aspirin (81 mg/d) after 12 weeks of gestation for
all women at high risk for preeclampsia.
Other Obstetrics
and Gynecology societies like The Society of Obstetricians and Gynecologists
of Canada, The National Institute for Health(NIH) and Care Excellence
recommends urinalysis for proteinuria at each antenatal visit.
The ACOG
only recommends B.P. measurements at every visit with detailed history to
evaluate the risk.
“Preeclampsia
and CVDs including hypertension are bound not only by common pathophysiology
but also epidemiology” said Nisha I. Parikh, MD, and Juan Gonzalez, MD, PhD,
from the University of California, San Francisco, in an accompanying editorial
published simultaneously in JAMA Internal Medicine.
"Pregnancy
is essentially a cardiovascular stress test, and the development of
preeclampsia among other pregnancy complications is the earliest marker of
patients at risk for future [cardiovascular disease].” They further added.
The full
text of recommendation statement in JAMA can be assessed here.
The accompanying
editorial in JAMA can be accessed here.
The accompanying
editorial in JAMA cardiology can be accessed here.
The accompanying
editorial in JAMA Internal Medicine can be accessed here.
Thursday, April 27, 2017
ACOG and AUGS issues recommendations for management of mesh and graft complications in gynecologic surgery.
Courtesy: Sanders firm |
The American
College of Obstetricians and Gynecologists (ACOG) and the American
Urogynecologic Society (AUGS) have jointly developed a committee opinion of the
management of mesh and graft complications in gynecologic surgery.
The document
provides surgeons with guidance for managing complications after mesh surgery.
It also stresses the importance of good clinical history and detailed physical
examination.
Knowledge of
exact location of the mesh/graft is a must, and case notes/operative notes from
the index procedure are best in providing the necessary information.
Diagnostic
testing includes cystoscopy, proctoscopy, colonoscopy, or radiologic imaging.
The procedures
most commonly associated with mesh complications are Midurethral Sling,
Abdominal sacral colpopexy and transvaginal mesh.
The
recommendations by American College of Obstetricians and Gynecologists and the
American Urogynecologic Society includes the following:
- Short-term voiding dysfunction after placement of a synthetic midurethral sling is common and, if improving, can be managed expectantly for up to 6 weeks. However, retention (inability to empty the bladder) or small-volume voids with large postvoid bladder residual volume should receive earlier intervention.
- Long-term voiding dysfunction (typically 3 months or longer) after a midurethral sling placement are managed by referral to a clinician with appropriate training and experience, such as a female pelvic medicine and reconstructive surgery specialist.
- Asymptomatic exposures of monofilament macroporous meshes can be managed expectantly in the hope that spontaneous reepithelialization can occur.
- A trial of vaginal estrogen can be attempted for small (eg, less than 0.5-cm) mesh exposures, if not successful primary reclosure is advised.
- Persistent vaginal bleeding, vaginal discharge, or recurrent urinary tract infections (UTIs) after mesh placement should prompt an examination and possible further evaluation for exposure or erosion.
- Pelvic pain (including dyspareunia), possibly related to nonexposed mesh, is complex, may not respond to mesh removal, and should prompt referral to a clinician with appropriate training and experience, such as a female pelvic medicine and reconstructive surgery specialist.
- Mesh removal surgery should not be performed unless there is a specific therapeutic indication.
The full text of committee opinion of
the management of mesh and graft complications in gynecologic surgery can be accessed here.
‘One size fits all’ breast imaging is a thing of past with new personalized breast exams by Automated Breast Ultrasound (ABUS).
Mammography
misses 30% of breast cancers in dense breast which means that nearly 40% of women
have the chance of missing breast cancer by simple screening mammography. Now
it is possible to individualize breast imaging for each patient using
multimodality approach.
Starting
with personal and family history, followed by gold standard screening mammography
with new technology of breast tomosynthesis, we can know the personal biology
of the patient.
Knowing that the woman has dense breast after
the initial screening Automated Breast Ultrasound (ABUS) can be performed which
increases the chances of cancer detections even after negative mammography.
Using all this
tool synergistically it is possible to increase the breast cancer detection rate
by 55 percent over mammography alone.
More
information about the ABUS by GE healthcare can be found here:
https://obgynupdated.blogspot.com/2017/03/innovative-breast-ultrasound-system-for.html
More information
about screening modalities other than mammography can be found here: https://obgynupdated.blogspot.com/2017/04/looking-beyond-screening-mammography-in.html
Know more about
personalized breast cancer screening by watching this video.
Wednesday, April 26, 2017
Autonomous sensors to detect UTI at early stage developed at Purdue.
courtesy: http://www.damngeeky.com/ |
Urinary
Tract Infection now can be diagnosed at early stage with an autonomous sensor developed
by researchers at Purdue University.
“Current
testing relies on time-consuming and costly urine culture tests performed at
medical facilities and on at-home testing using store-purchased dipsticks that
generally have high false alarm rates,” says Babak Ziaie, professor of
electrical and computer engineering in Purdue’s School of Electrical and
Computer Engineering. “Additionally, collecting urine samples for these methods
can be challenging for infants and geriatric patients who suffer from
neurodegenerative diseases. There’s also a privacy and dignity issue.”
UTI are common
at extremes of age and is associated with significant morbidity and long-term
medical consequences. In fact, they are most common infections in older adults
specially in institutional settings. A woman’s lifetime risk for being
diagnosed with UTI is more than 50%.
The
researchers have developed bandage size disposable sensor, that is operated by
battery which is activated after coming in contact with urine. The sensors
detect nitrites, the chemical compound formed in UTI, and wirelessly sends the
result to a smartphone app that keeps the data log and sends the results to the
patient, caregiver, and/or health-care network if required.
The sensor
can be easily embedded in the diaper.
“Ours is the
only one that works fully autonomously,” Ziaie said. “Conventional methods
require a certain level of patient or caregiver intervention.” This will be especially
useful in infants and older adults who are not aware of symptoms or who do not have
the ability to report the symptoms.
Work is now
shifting to sizing, packaging, diaper embedding methods, smartphone app details
and other efforts to prepare the technology for commercialization. A pilot
study also is planned.
Several
patents are already pending on this prototype but, this is the only one which
is autonomous.
“Once you
detect a urinary tract infection in its early stage, it’s very easy to cure,”
said team member Byunghoo Jung, associate professor of electrical and computer
engineering in the School of Electrical and Computer Engineering. “You just need
an antibiotic. Early detection is the key.”
Source: Purdue Research Foundation
Tuesday, April 25, 2017
Artificial womb keeps premature lamb alive for 4 weeks: Giant leap towards developing artificial wombs for extreme preemies.
CHILDREN'S HOSPITAL OF PHILADELPHIA |
A group of clinicians and researchers at
Children's Hospital of Philadelphia in US has taken a giant leap toward
developing an artificial womb for humans—by building and testing one designed
to keep very premature lambs alive outside the bodies of their mothers.
Lambs born at the equivalent of 23
weeks of human pregnancy were kept alive and appeared to develop normally while
floating inside the transparent, womb-like device for four weeks after birth.
This
pioneering approach could radically improve outcome for babies born so early
that they cannot breathe, feed or fight infection without medical help.
The study was published in Journal Natures Communications online 25 April 2017.
Extreme prematurity is leading cause
of neonatal morbidity and mortality. Over one-third of all infant deaths and
one-half of cerebral palsy attributed to prematurity.
Taking a cue from nature, Alan Flake,
a researcher and neonatal surgeon at the Children's Hospital of Philadelphia
along with Emily A. Partridge, and Marcus G. Davey created this new incubator
after 5 years of research. It mimics the fluid-filled milieu of the mother's womb while still maintaining a
connection to the outside world.
He said, “the proposed system could
act as an urgently needed bridge between the mother’s womb and the outside
world for babies born at between 23 to 28 weeks’ gestation.”
“If we can support growth and organ maturation
for only a few weeks, we can dramatically improve outcomes for extremely
premature babies,” he said.
This concept of extracorporeal support
of the fetus is very appealing which maintains the intrauterine milieu by
providing gas exchange by ‘artificial placenta’. The system consists of 3 main
components namely:
- a pumpless arteriovenous circuit,
- a closed fluid environment with continuous fluid exchange
- and a new technique of umbilical vascular access.
The current device was created after identifying
and rectifying many obstacles identified in series of pilot studies and years
of tweaking.
A pumpless arteriovenous circuit
The blood flow is completely driven by
pumping of the fetal heart and is
combined with a very low resistance oxygenator that most closely mimic the
normal fetal/placental gas exchange interface.
A closed sterile fluid environment
The device uses a ‘Biobag’ design consisting of
a single use completely closed system that houses and circulates fluid similar
to amniotic fluid and that can closely replicate the size and shape of the uterus.
The fluid's chemical composition is similar to amniotic fluid and contains
electrolyte.
Umbilical vascular access
This closely approximate flow dynamics
in utero because of double umbilical artery and single umbilical vein
cannulation (abbreviated UA/UV) cannulation. The team devised adapters that helps
to quickly cannulate the umbilical cord after birth, that is connected to external
oxygenator, which serves the function of a lung. Umbilical cord spasm are
avoided by adapting a number of techniques.
The study reported successful results
with 8 lambs. They were in the ‘artificial womb’ for 1 month, with normal
heart, lungs and brain development.
CHILDREN'S HOSPITAL OF PHILADELPHIA |
Clinical application will require
further evolution and modification of the design, safety and scientific evaluation
of the entire system. But the target population for which the device is being
developed is 23–25-week extreme premature infants.
The researchers do not aim to extend
the current limit of viability, but to improve outcomes for those already
treated in neonatal intensive care units (NICU).
Other therapeutics applications include
treatment of fetal growth retardation, salvage of preterm infants
threatening to deliver after fetal intervention or fetal surgery.
This innovative technology could play
a role to save infants who have congenital malformations of the heart, lung
and diaphragm.
Numerous applications related to fetal
pharmacologic, stem cell or gene therapy could be facilitated by removing the
possibility for maternal exposure and enabling direct delivery of therapeutic
agents to the isolated fetus.
The next steps for the Philadelphia team
include one more animal study , as well as creating a device with medical-grade
plastics for eventual use on humans.
Article source: Partridge, E. A. et al. An extra-uterine
system to physiologically support the extreme premature lamb. Nat. Commun. 8,
15112 doi: 10.1038/ncomms15112 (2017).
The full text of the Nature Communication article can be accessed here .
Monday, April 24, 2017
Video of the day: Stethoscopes going digital.
Stethoscopes
have become synonymous for Medical Profession. But in this era of portable
ultrasound, smartphone apps about almost anything and everything most doctors
still use analogue stethoscopes.
But Hon Weng
Chong, a physician in Melbourne have designed a simple, compact, portable
device that can be paired with a smartphone in recording heartbeats and
respiratory rates. Further this record can be stored on the smartphone, only to be recalled at later date or
uploaded to a cloud based server.
The digital
stethoscope is called Clinicloud. It comes with a digital thermometer that does
not requires skin contact to check the
temperature.
The data can
be shared with your physician or healthcare provider. The physician also can
easily compare it with your last reading.
Here is the
video reviewing the Clinicloud
Evidence does not support adhesiolysis as a treatment of chronic pain after gynecological and general surgery: a systematic review and meta-analysis.
courtesy: laparoscopyindia.com |
At present,
there is little evidence to support the routine use of adhesiolysis to relieve
post-operative chronic abdominal pain after gynecological and general surgery
according to results of a systematic review and meta-analysis published in
current issue of Journal of Human Reproduction Update.
Postoperative
adhesions are cause of significant morbidity like bowel obstruction, chronic
pelvic pain and infertility in females. Open gynecological surgeries are
highest risk factor for adhesions formation.
Chronic pain
leads to diminished quality of life post operatively and affects nearly 20-40%
of patients who have undergone abdominal surgeries.
This systematic
review and meta-analysis investigated the role of surgery in relieving the
chronic pain immediately and after extended follow up. It also assessed the
safety and complications associated with adhesiolysis.
After
literature review a total of 4294 unique studies were identified, out of which
13 studies met the study criteria which included 2 RCTs.
After the
pooled analysis of the data, 72% patients reported improvement in pain at
follow-up of > 3 months. In about 20% of the patients no cause of pain was
found while 4% patients suffered some complications because of laparoscopy.
The authors
concluded that laparoscopic adhesiolysis relieves pain from adhesions in ~70%
of patients for short term only. The evidence does not support adhesiolysis for
relieving chronic pain in longer run. It also results in bowel injuries and
many laparoscopies turn out to be negative amounting to unnecessary surgeries.
More
research should be focused at techniques and materials designed to reduce and
prevent postsurgical adhesions and to improve results of adhesiolysis.
Sunday, April 23, 2017
Looking beyond screening mammography in the war against breast cancer.
Courtesy: MariaShriver.com |
Whenever we
think of breast imaging, our first thought is mammography. The earliest record
of mammography dates back to 1913 when German Surgeon Albert Salomon attempted
to visualize cancer through radiogram but it was only in mid 60s that mammography
was introduced as a screening tool on mass scale for early diagnosis of breast
cancer.
The technique
has substantially evolved in last several decades, from direct-exposure films to
digital. Digital mammography exposes the patient to much lower dose of radiation
as compared to analog mammography and the images are clearer and can be viewed
on computer.
New data
analysis R. Edward Hendrick, Ph.D., shows nearly 275,000 breast cancer deaths
have been averted since 1990, attributed to increased mammographic screening
and improved therapies.
However,
like other techniques, mammography is also not perfect and has its own
limitations.
According to ACS screening mammograms do not find about 1 in 5
breast cancers. Chances of missing the disease is higher if the patient have
dense breast.
A recent
study has shown that nearly 43% patients in USA have dense breast.
Many US
states have laws requiring the mammography centers to inform patients about dense
fibroglandular breast tissue and its impact on cancer diagnosis and detection
rates.
courtesy of Hologic |
Digital breast tomosynthesis (DBT) or
3D mammography is a
new technique for mammography especially useful for screening women with dense
breast. It includes multiple low-dose full-field projection images of the
breast obtained from different angles that form an arc. The images are then
used to reconstruct a 3D image of the breast, resulting in a clearer view
without the distraction of overlapping tissue.
Currently
there are four tomosynthesis systems on the market. Hologic’s Selenia
Dimensions mammography, GE’s SenoClaire 3-D breast tomosynthesis, Siemens
Mammomat Inspiration Prime with Tomosynthesis Option and Fujifilm Medical
Systems U.S.A.
Another
screening technique is whole breast ultrasound and breast magnetic resonance
imaging (MRI).
Whole breast ultrasound is used along with screening mammography
to pick up lesions that cannot be felt by hands and also not seen on mammography.
It is done in the same sitting as screening mammogram. It is specifically
useful for patients whose mammogram reported “Extremely dense breasts” (or
density score of 4) or “Heterogeneously dense breasts” (or density score of 3).
It can be
performed manually or by using Automated Breast Ultrasound System(ABUS).
GE
Introduced a new version of its automated breast ultrasound system ‘the Invenia Automated Breast Ultrasound System(ABUS)’.
Breast MRI is another screening tool, it is not
recommended for routine screening because it results in more false positives
leading to anxiety and unnecessary breast biopsies. It is recommended for screening women who are
at high risk for breast cancer, usually due to a strong family history and/or a
mutation in genes such as BRCA1 or BRCA2.
The American
Cancer Society (ACS) recommends that all high-risk women with greater than 20%
lifetime risk of breast cancer should have a breast MRI and a mammogram every
year. For most women, these combined screenings should start at age 30 and
continue as long as the woman is in good health.
Combined
these three techniques are able to find another 20-40 percent more cancers than
screening mammography alone.
Major
American medical organizations with expertise in breast cancer care, including
the American Congress of Obstetricians and Gynecologists (ACOG), American
College of Radiology (ACR) and Society of Breast Imaging (SBI) continue to
recommend that women start getting annual mammograms at age 40 and continue
screening till women is in good health or life expectancy is less than 10
years.
USPSTF
advises to start screening at age 50 till 74 years with an interval of 2 years
between screening.
Saturday, April 22, 2017
Pregnant women should limit the use of cell phone: cautions results of largest study till date.
courtesy: research medical center |
Children
born to mothers who frequently used cell phones prenatally were more likely to
have hyperactivity/inattention problems as compared to those who used it less
frequently.
The lead author
Laura Birks is not advising the mothers to stop using cell phones, but just be cautions
and use it in moderation because the research has still not proved causation.
An earlier
study published in Journal Epidemiology in 2008 also found that mothers who did use
the handsets were 54 per cent more likely to have children with behavioral
problems and that the likelihood increased with the amount of potential
exposure to the radiation.
In the
current study the researchers analyzed 83,884 mother-child pairs in five
cohorts from Denmark, Korea, Netherlands, Norway and Spain during various time periods
from 1996 to 2011.
The cell
phone use was divided into none, low, medium, and high based on the usage
reported by mother.
The earliest
cohort from Denmark between 1996–2002 was the only cohort having enough women
who did not use cell phones while pregnant.
Children
born to mothers who were on cell phones for at least 4 calls/day or in another
cohort for an hour/day were 28% more likely to be hyperactive as compared to
children whose mothers made 1 or fewer call per day.
The
association was found consistently across all cohorts, both for prospective and
retrospective collected data.
Researchers
are raising more questions after the results of study was published.
Dr. Robin
Hansen, a pediatrician and professor at the University of California, Davis in
Sacramento opines that the study does not answer the question whether it is the
actual handset or your parenting behavior that causes the psychological
problems.
She said in
an interview with Medscape “Now we have to dig deeper and figure out why? Is it
the electronic signals that go through your brain and your body, or how it
changes your interactions with your child postnatally?”
She also
said that we also need to look at the fact that those mothers who are busy on
cellphones do not have enough time for their children, shaping their behavior
differently. Children become hyperactive and through tantrum to get the parents
away from the cell phone and before long it becomes a habit.
The Russian
National Committee on Non-Ionizing Radiation Protection advises to limit the
use of phone in children too. It concludes that children who talk on the
handsets are likely to suffer from "disruption of memory, decline of
attention, diminishing learning and cognitive abilities, increased
irritability" in the short term, and that longer-term hazards include
"depressive syndrome" and "degeneration of the nervous
structures of the brain".
On July
1,2015 more than one hundred medical doctors, scientists and public health
experts from around the world have signed a Joint Statement advising pregnant
women to take simple precautions to protect themselves and their babies from
wireless radiation. The Statement is part of a national right-to-know campaign
called the BabySafe Project created by two non-profit organizations to inform
pregnant women about the issue.
"The
wireless world may be convenient, but it's not without risks," says
Patricia Wood, Executive Director of Grassroots Environmental Education and
co-creator of the BabySafe Project. "When more than one hundred of the
world's leading medical doctors and researchers on wireless radiation say we
have enough evidence for women to take protective action, we think women should
know about it."
Friday, April 21, 2017
FDA clears Bovie Medical J-Plasma generator incorporating Cool-Coag™ technology for use in various surgical procedures.
Courtesy: Bovie Medical |
Bovie Medical recently received FDA
clearance for its novel J-Plasma generator and handpiece featuring the
company’s “COOL-COAG” technology.
In Gynecological surgeries, J-Plasma
increases a surgeon’s ability to target endometriosis and chronic pelvic pain
which may result in less inflammation, accelerated healing (as compared to
electrocautery) reduced adhesion formation and improved outcomes in patients
with chronic pelvic pain and endometriosis.
This one of a kind device performs
tissue dissection with minimal thermal spread with excellent control of its plasma
stream and can switch to monopolar or helium spray coagulation mode with just a
push of button.
The J-Plasma® makes use of helium
ionization process to produce a stable, focused beam of ionized gas that
provides surgeons with greater precision, minimal invasiveness and an absence
of conductive currents through the patient during surgery.
The plasma stream generated by passing
inert helium gas over a blade can perform all the three functions of cutting, coagulating
and vaporizing the tissues at a much lower temperature than CO2 lasers, thereby
limiting damage. The surgeon also benefits using a single device and absence of
any smoke, odor or eschar.
extension of the blade |
The handpiece distinctive design allows the retraction or extension of the surgical blade between different mode of operation. When the plasma stream is switched off, the blade can be used as scalpel for incision and when the stream is put on it can be used for coagulation or blunt dissection.
retraction of the blade |
Robert Gershon, CEO of Bovie Medical
said “The development of Bovie’s Cool-Coag technology is a direct result of
feedback from surgeons who have used our J-Plasma product for procedures that
require greater coagulation capability, specifically in the areas of
gynecologic oncology and surgical oncology. The unique flexibility of Cool-Coag
enables the surgeon to use J-Plasma to perform the most delicate procedures,
where precision and low risk of injury to surrounding tissue are paramount and
also have the full power of monopolar coagulation to control, pinpoint and
diffuse bleeding as needed.”
Dennis Chi, MD, head of ovarian cancer
surgery at Memorial Sloan Kettering Cancer Center “This new Cool-Coag
technology has the potential to increase usage of the J-Plasma device in many
of our most complex cancer procedures. It combines J-Plasma’s ability to be
used close to vital structures with minimal collateral damage and standard full
monopolar coagulation capability, all in one hand-held instrument.”
Plasma is one of the four fundamental
states of matter besides solid, liquid, and gas. When a gas is ionized by
passing current through it, electrons are stripped from its atoms, turning it
into plasma.
The plasma energy is generated as a
precise stream that dissipates rapidly as it comes in contact with the tissue,
but with controlled penetration and minimal thermal effect.
Use of plasma cutter is going to open
many new treatment avenues in near future specially in field of oncology.
This video will demonstrate the extremely
low thermal spread and remarkable precision of both ease and safety with J plasma
helium based surgical technology.
Morning after pill now available through vending machines at UC Davis Campus. Seriously!
Vending machine |
Is UC Davis validating unsafe behavior by selling ‘morning after ‘pill through vending
machine across campus? Would you be getting the pill just by pressing a button? Well Yes!
UC Davis is
one of the first college campuses in the country to have a vending machine that
offers the Plan B emergency contraceptive, otherwise known as the "morning
after pill."
This was
made possible by 2 years’ efforts by Parteek Singh, a 21-year-old senior, was
running for the student government senator position. "Here at Davis we
only have one pharmacy that is open 24/7, and a couple of my friends shared
incidents when the pharmacy has ran out of emergency contraceptives on a Friday
night and they weren't getting a new shipment until Monday," Singh said.
The vending
machine is called ‘Wellness to go’ and also dispenses pregnancy tests, tampons,
Advil and condoms.
Federal law
makes the levonorgestrel pill available without a prescription to anyone 17 or
older and it is freely available at pharmacies across US.
The other pill
containing ulipristal acetate is a prescription medicine.
Debate is
rife on social medias, news agencies and health forums about the easy
availability of the pill on college campuses. The critics are saying that it’s
like taking personalized medicine too far! College students will be able to buy
the pill, without any medical knowledge or discussing the side effects and risk
factors with a health care provider.
Also, it may
lead to less frequent use of condoms, that besides preventing pregnancy protects
from Sexually Transmitted Infections(STI). Critics also are debating the issue
because it is like encouraging more sex on college campus with easy access to
contraceptives.
People who
favor it say that it will help prevent unwanted pregnancies. Many students
support it easy access while others are not comfortable to talk about it.
Meanwhile, A
proposed California bill that would require the abortion pill to be provided on
all University of California and California State University campuses passed
its first committee.
It requires
that campuses that have student health services to offer medical abortion pill
and scientifically accurate information to be provided to the students.
Subscribe to:
Posts (Atom)